Monday, 19 November 2007

Pharmacogenetics environment 2007

Today at the Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand,there is a work shop on pharmacogenetics environment 2007, held by the research affairs of the Faculty of Medicine, Chulalongkorn University and GlaxoSmithKlien Pharmaceuticals.
The main topics are ethical concerns and regislation or any kinds of regulation in conduct pharmacogenetics(PGx) and pharmacogenomics(PGm) clinical research.
The speakers were Dr. Chanin Limwongse, a clinical geneticist from the Faculty of Medicine, Siriraj hospital, Mahidol University, Dr Rachaneekorn, a genetic scientist from the Faculty of Sciences, Chulalongkorn University, Dr Wasan Chantratit, a virologist, and bioinformaticians, from the faculty of Medicine, Ramathibodi hospital, Mahidol University, and the representatives of GSK (one from UK and one from USA).
Phamacogenetics and pharmacogenomics are the fields involved with study about variation of the DNA, a single point, multiple points or across the whole genome that resulted to different drug response or adverse effect from the drugs. The data will provide the theoretical prediction for the beneficial and side effects of the drugs. The speakers stated that the major problems of today research are not only the back up resources such as granting agencies, equipments, or personnels, but the lack of public and also the investigators themself awareness of the interpretation of the results, the decision making of participations, and ethical issues and regulations of perform such research.
The pharmaceuticals and researchers predicted that pharmacognetics/pharmacogenomics research will become the main stream research practices to improve rate of licensing of the drugs, safe money to run clinical research and safe more patinets in time.

No comments: